If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Eric Whitman is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Skin Medicine & Life Sciences
Subunit Vaccines Medicine & Life Sciences
interferon alfa-2b Medicine & Life Sciences
Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1987 2019

Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices

Whitman, E., Liu, F. X., Cao, X., Diede, S. J., Haiderali, A. & Abernethy, A. P., Feb 1 2019, In : Future Oncology. 15, 5, p. 459-471 13 p.

Research output: Contribution to journalArticle

Medical Oncology
Melanoma
Electronic Health Records
Mitogen-Activated Protein Kinase Kinases
Observational Studies
24 Citations (Scopus)
Melanoma
Placebos
Mutation
Disease-Free Survival
Keratoacanthoma
10 Citations (Scopus)

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: Version 2.0

Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L., Gajewski, T. F., Gastman, B., Lawson, D. H., Lutzky, J., McDermott, D. F., Margolin, K. A., Mehnert, J. M., Pavlick, A. C., Richards, J. M., Rubin, K. M., Sharfman, W., Silverstein, S., Slingluff, C. L. & 8 others, Sondak, V. K., Tarhini, A. A., Thompson, J. A., Urba, W. J., White, R. L., Whitman, E., Hodi, F. S. & Kaufman, H. L., May 30 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 44.

Research output: Contribution to journalArticle

Immunotherapy
Melanoma
Consensus
Skin
Advisory Committees
8 Citations (Scopus)

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma

Chesney, J., Awasthi, S., Curti, B., Hutchins, L., Linette, G., Triozzi, P., Tan, M. C. B., Brown, R. E., Nemunaitis, J., Whitman, E., Windham, C., Lutzky, J., Downey, G. F., Batty, N. & Amatruda, T., Jan 1 2018, In : Melanoma Research. 28, 1, p. 44-51 8 p.

Research output: Contribution to journalArticle

Melanoma
Safety
Therapeutics
Hyperhidrosis
Drug Approval
3 Citations (Scopus)

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E

Hallmeyer, S., Gonzalez, R., Lawson, D. H., Cranmer, L. D., Linette, G. P., Puzanov, I., Taback, B., Cowey, C. L., Ribas, A., Daniels, G. A., Moore, T., Gibney, G. T., Tawbi, H., Whitman, E., Lee, G., Mun, Y., Liu, S. & Hamid, O., Jan 1 2017, In : Melanoma Research. 27, 6, p. 585-590 6 p.

Research output: Contribution to journalArticle

Exons
Melanoma
Mutation
Therapeutics
Confidence Intervals